

SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If the information provided is not complete, correct, or legible, the authorization process can be delayed.

Drug Requested: Zeposia® (ozanimod)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight (if applicable): _____ Date weight obtained: _____

Quantity Limit: 1 capsule per day

Recommended Dosage: Oral: Initial: 0.23 mg once daily on days 1 through 4; then 0.46 mg once daily on days 5 through 7; maintenance dose: 0.92 mg once daily starting on day 8

NOTE: The Health Plan considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Stelara) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has NOT been established and will NOT be permitted.

- Will the member be discontinuing a previously prescribed biologic if approved for requested medication?
 Yes **OR** No
- If yes, please list the medication that will be discontinued and the medication that will be initiated upon approval along with the corresponding effective date.

Medication to be discontinued: _____ Effective date: _____

Medication to be initiated: _____ Effective date: _____

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- Member has a diagnosis of moderate-to-severe active **ulcerative colitis**
- Medication has been prescribed by a **Gastroenterologist**
- Member meets **ONE** of the following:
 - Member has tried and failed budesonide or high dose steroids unless there is a contraindication or intolerance
 - Member has tried and failed at least **ONE** of the following **DMARD** therapies unless there is a contraindication or intolerance:
 - 5-aminosalicylates (balsalazide, olsalazine, sulfasalazine)
 - oral mesalamine (Apriso, Asacol/HD, Delzicol, Lialda, Pentasa)
 - Member has previously tried and failed at least one biologic medication other than the requested medication (e.g., Humira, Rinvoq, Stelara)
- Member meets **ONE** of the following:
 - Member tried and failed, has a contraindication, or intolerance to **TWO** of the following **PREFERRED** biologics:
 - ONE** preferred adalimumab product
 - Skyrizi®
 - Tremfya®
 - ONE** preferred ustekinumab product
 - Zymfentra™
 - Member has been established on Zeposia® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Zeposia was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

Medication being provided by Specialty Pharmacy – Proprium Rx

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****